Bronchial Thermoplasty in Severe Persistent Asthma
Conditions
Severe Asthma
What is the purpose of this trial?
As Conditions of Approval of the PMA for the Alair System, the FDA requires Asthmatx to generate data to assess the durability of the BT treatment effect as well as safety data in the intended use population in the United States.
Participation Guidelines
- Age:
- 18 Years - 65 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Asthmatx, Inc.
Boston Scientific Corporation - Dates:
- April 2011
- Last Updated:
- January 15, 2013
- Study HIC#:
- 1102008067
Clinicaltrials.gov ID: NCT01350336
For more information about this trial, contact:
Donna Cook
203-737-4818
donna.cook@yale.edu
Nicole Grant
203-737-4818
nicole.grant@yale.edu
Investigator
Geoffrey Chupp, MD
Principal Investigator
